BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 35428471)

  • 1. Cystic adrenal masses: spectrum of multimodality imaging features and pathological correlation.
    Wang MX; Mahmoud HS; Klimkowski S; Salem U; Korivi BR; Corwin M; Ahmed AM; Shaaban AM; Menias CO; Elsayes KM
    Clin Radiol; 2022 Jul; 77(7):479-488. PubMed ID: 35428471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography.
    Timmers HJ; Chen CC; Carrasquillo JA; Whatley M; Ling A; Eisenhofer G; King KS; Rao JU; Wesley RA; Adams KT; Pacak K
    J Natl Cancer Inst; 2012 May; 104(9):700-8. PubMed ID: 22517990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma.
    Timmers HJ; Chen CC; Carrasquillo JA; Whatley M; Ling A; Havekes B; Eisenhofer G; Martiniova L; Adams KT; Pacak K
    J Clin Endocrinol Metab; 2009 Dec; 94(12):4757-67. PubMed ID: 19864450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 6-18F-fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to 123I-metaiodobenzyl-guanidine scintigraphy in the detection of extraadrenal and hereditary pheochromocytomas and paragangliomas: correlation with vesicular monoamine transporter expression.
    Fottner C; Helisch A; Anlauf M; Rossmann H; Musholt TJ; Kreft A; Schadmand-Fischer S; Bartenstein P; Lackner KJ; Klöppel G; Schreckenberger M; Weber MM
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2800-10. PubMed ID: 20371665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. (18)F-FDG PET/CT of adrenal lesions.
    Dong A; Cui Y; Wang Y; Zuo C; Bai Y
    AJR Am J Roentgenol; 2014 Aug; 203(2):245-52. PubMed ID: 25055255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening in asymptomatic SDHx mutation carriers: added value of ¹⁸F-FDG PET/CT at initial diagnosis and 1-year follow-up.
    Lepoutre-Lussey C; Caramella C; Bidault F; Déandreis D; Berdelou A; Al Ghuzlan A; Hartl D; Borget I; Gimenez-Roqueplo AP; Dumont F; Deschamps F; Nascimento C; Lumbroso J; Guillaud Bataille M; Schlumberger M; Baudin E; Leboulleux S
    Eur J Nucl Med Mol Imaging; 2015 May; 42(6):868-76. PubMed ID: 25676472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 6-[F-18]Fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with (123)I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine excess.
    Fiebrich HB; Brouwers AH; Kerstens MN; Pijl ME; Kema IP; de Jong JR; Jager PL; Elsinga PH; Dierckx RA; van der Wal JE; Sluiter WJ; de Vries EG; Links TP
    J Clin Endocrinol Metab; 2009 Oct; 94(10):3922-30. PubMed ID: 19622618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma.
    Timmers HJ; Kozupa A; Chen CC; Carrasquillo JA; Ling A; Eisenhofer G; Adams KT; Solis D; Lenders JW; Pacak K
    J Clin Oncol; 2007 Jun; 25(16):2262-9. PubMed ID: 17538171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of adrenal masses by 18F-FDG positron emission tomography scanning.
    Han SJ; Kim TS; Jeon SW; Jeong SJ; Yun M; Rhee Y; Kang ES; Cha BS; Lee EJ; Lee HC; Lim SK
    Int J Clin Pract; 2007 May; 61(5):802-9. PubMed ID: 17343665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic and anatomic characteristics of benign and malignant adrenal masses on positron emission tomography/computed tomography: a review of literature.
    Kandathil A; Wong KK; Wale DJ; Zatelli MC; Maffione AM; Gross MD; Rubello D
    Endocrine; 2015 May; 49(1):6-26. PubMed ID: 25273320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluorodeoxyglucose-positron-emission tomography/computed tomography imaging for adrenal masses in patients with lung cancer: review and diagnostic algorithm.
    Stone WZ; Wymer DC; Canales BK
    J Endourol; 2014 Jan; 28(1):104-11. PubMed ID: 23927734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 18F-FDG PET in characterizing adrenal lesions detected on CT or MRI.
    Yun M; Kim W; Alnafisi N; Lacorte L; Jang S; Alavi A
    J Nucl Med; 2001 Dec; 42(12):1795-9. PubMed ID: 11752075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of positron emission tomography/computed tomography in adrenal and neuroendocrine tumors: fluorodeoxyglucose and nonfluorodeoxyglucose tracers.
    Wong KK; Arabi M; Zerizer I; Al-Nahhas A; Rubello D; Gross MD
    Nucl Med Commun; 2011 Sep; 32(9):764-81. PubMed ID: 21799367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adrenal masses of varied etiology: anatomical and molecular imaging features on PET-CT.
    Sharma P; Singh H; Dhull VS; Suman KC S; Kumar A; Bal C; Kumar R
    Clin Nucl Med; 2014 Mar; 39(3):251-60. PubMed ID: 24217551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of incidentally discovered adrenal masses with PET and PET/CT.
    Wong KK; Arabi M; Bou-Assaly W; Marzola MC; Rubello D; Gross MD
    Eur J Radiol; 2012 Mar; 81(3):441-50. PubMed ID: 21295930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of combination of contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography for evaluation of ovarian masses.
    Tsuboyama T; Tatsumi M; Onishi H; Nakamoto A; Kim T; Hori M; Sakane M; Hori Y; Morii E; Hatazawa J; Tomiyama N
    Invest Radiol; 2014 Aug; 49(8):524-31. PubMed ID: 24637584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Case of 131I-meta-iodobenzylguanidine (MIBG) scintigraphy-negative and 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET)-positive pheochromocytoma].
    Jotoku M; Okura T; Nagao T; Enomoto D; Irita J; Miyoshi K; Kurata M; Fukuoka T; Higaki J
    Nihon Jinzo Gakkai Shi; 2009; 51(5):563-8. PubMed ID: 19715165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating between benign and malignant adrenal lesions.
    Ozcan Kara P; Kara T; Kara Gedik G; Kara F; Sahin O; Ceylan Gunay E; Sari O
    Nucl Med Commun; 2011 Feb; 32(2):106-12. PubMed ID: 21085046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adrenal gland scintigraphy.
    Avram AM; Fig LM; Gross MD
    Semin Nucl Med; 2006 Jul; 36(3):212-27. PubMed ID: 16762612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiological evaluation of adrenal incidentalomas: current methods and future prospects.
    McDermott S; O'Connor OJ; Cronin CG; Blake MA
    Best Pract Res Clin Endocrinol Metab; 2012 Feb; 26(1):21-33. PubMed ID: 22305450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.